Blueprint Medicines Corporation (BPMC) Undervalued by 29.1%

Publicly-traded company Blueprint Medicines Corporation (NASDAQ:BPMC) had a closing price of $78.68 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $111.00, this means that the stock is underpriced by 29.117%. In the past 52 weeks the company’s stock price has moved within the range of $44.58 to $102.98.

This particular stock’s 5-day moving average is 75.35, its 20-day moving average is 74.00 and its 100-day moving average is 85.08. Blueprint Medicines Corporation (BPMC) currently has 49116 shares outstanding, which means that its market capitalization is $3.85B.


The Details: Blueprint Medicines Corporation (BPMC) Financial Health

It is also smart to find out what a company’s Return on Assets is. This percentage tells us how well a company is making use of its net assets to generate a profit. The lower the percentage, the worse the company does with its available assets. At the moment, Blueprint Medicines Corporation Return on Assets is -54.50% .


What Does Wall Street Say about Company?

When considering a new stock purchase, a lot of investors find out how Wall Street analysts feel about the company before they buy in. You can do this by looking for the average analyst rating on the company’s stock. At the moment, the average analyst rating for BPMC is Buy . Out of 13 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 2 rated it an overweight, 1 rated it hold, and 10 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for Blueprint Medicines Corporation (BPMC) was a Buy – from a survey of 10 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, 0 rated it a Sell, 1 rated it an overweight, 0 rated it an underweight, and 9 rated it a Buy.


Understanding Profitability at Blueprint Medicines Corporation (BPMC)

Having a look at a company’s recent Earnings per Share (EPS) performance is a useful way of understanding its profitability. In the most recent financial results released by Blueprint Medicines Corporation, for the quarter ending on 09/2019, the company posted EPS of -2.16. The average estimate of Wall Street analysts had projected -1.87.